Table 1.
Tumor responses in patients with various NETs, treated with different radiolabeled SST analogs.
| Ligand | Patient number | Tumor response | References | |||
|---|---|---|---|---|---|---|
| CR | PR | SD | PD | |||
| [111In-DTPA0]octreotide | 26 | 0 | 2 (8%) | 21 (81%) | 3 (11%) | [71] |
| [111In-DTPA0]octreotide | 18 | 0 | 2 (11%) | 16 (89%) | 0 | [72] |
| 90Y-DOTATOC | 116 | 5 (4%) | 26 (22%) | 72 (62%) | 13 (11%) | [79] |
| 90Y-DOTATOC | 41 | 1 (2%) | 9 (22%) | 25 (61%) | 6 (15%) | [80] |
| 177Lu-DOTATATE | 310 | 5 (2%) | 86 (28%) | 158 (51%) | 61 (20%) | [81] |
| 177Lu-DOTATATE | 26 | 3 (12%) | 7 (27%) | 12 (46%) | 4 (15%) | [82] |
| 90Y-DOTATATE and 177Lu-DOTATATE | 26 | 2 (7.7%) | 9 (34.6%) | 11 (42.3%) | 4 (15.4%) | [83] |
| 213Bi-DOTATOC | 7 | 1 (14%) | 2 (28%) | 3 (44%) | n.a. | [36] |
CR: complete remission; PR: partial remission; SD: stable disease; PD: progressive disease; n.a. not available.